(RTTNews) - The after-hours gainers on Monday included Autonomix Medical, following its recent reverse stock split; Picard Medical, which reported encouraging Q2 results recently; and Tenax Therapeutics, now showing signs of recovery after plunging 90% earlier this month, among others.

Shares of Autonomix Medical Inc. (AMIX) are up more than 100% in after-hours trading on Monday, with no specific news.

This development-stage medical device company is focused on advancing technologies for sensing and treating disorders of the nervous system. A one-for-twenty-one (1:21) reverse stock split was implemented on June 24, 2026, to regain Nasdaq compliance.

The company had an accumulated deficit of $69.8 million, working capital of $3.1 million, and cash of $3.5 million as of June 30, 2026.

AMIX closed Monday's trading at $5.37, up 1.90%. In the after-hours, the stock was up another 116% to $11.61.

Picard Medical Inc. (PMI), which gained nearly 60% in regular trading on Monday, added another 12% in the after-hours.

Picard is the parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada. A 1-for-50 reverse stock split was implemented effective July 31, 2026, to regain compliance with the NYSE American's continued listing standards.

The company reported encouraging Q2 2026 results last week, with revenue increasing 39% to ~$3.0 million, driven primarily by higher U.S. sales. Gross profit improved to ~$0.6 million, compared with a ~$0.1 million loss in the prior-year period, while gross margin rose to 20.9%. Net loss also narrowed 16% to ~$5.7 million.

PMI closed Monday's trading at $5.13, up 59.81%. In after-hours, the stock was up 8.97% to $5.59.

Tenax Therapeutics Inc. (TENX) was up over 7% in after-hours trading on Monday on no specific news. This clinical-stage pharmaceutical company is focused on developing novel cardiopulmonary therapies.

Early this month, i.e. on August 10, 2026, the company announced that its Phase 3 LEVEL clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) did not meet the primary or secondary endpoints. The news sent the stock reeling to as low as $1.31 that day from the previous day's close of $13.44, representing over a 90% decline.

TENX closed Monday's trading at $1.85, up 5.71%. In after-hours, the stock was up 7.03% at $1.98.

Kura Oncology Inc. (KURA) has been on a tear since reporting its second-quarter 2026 financial results earlier this month.

The company's lead drug, Komzifti, was approved by the FDA last November for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.

Komzifti generated $9.1 million in net product revenue in the second quarter of 2026, up 57% from the first quarter, while approximately 115 new patients started treatment, a 35% increase from the prior quarter.

KURA closed Monday's trading at $12.40, up 4.29%. In after-hours, the stock gained 6.23% and was at $13.17.

Nephros Inc. (NEPH), a water technology company providing filtration solutions to the medical and commercial markets, was up over 4% in after-hours trading on Monday.

The company reported Q2 2026 financial results earlier this month, posting the highest quarterly revenue in its history.

Net revenue for the second quarter of 2026 was $6 million, up 36% from $4.4 million in the year-ago quarter, while net income rose to $1.2 million from $0.2 million. Net income included a one-time tariff refund of approximately $0.6 million.

Adjusted EBITDA for Q2 2026 also increased to $1.3 million from $0.4 million in the second quarter of 2025.

NEPH closed Monday's trading at $4.41, up 8.89%. In after-hours, the stock gained another 4.99% and was at $4.63.

Some people have diagonal creases across their earlobes, a physical sign known as Frank's sign. It was first described by Dr. Sanders T. Frank, who reported an association between the crease and coronary artery disease (CAD).

While Frank's sign is not a definitive diagnostic tool for CAD, it has been studied as a potential physical marker of underlying cardiovascular disease. (Source: BiologyInsights.com)